Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525546 · ClinicalTrials.gov registry record · Phase 1
Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT05525546: Completed Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT05525546 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 82 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05525546, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
Primary Outcome
To assess the frequency and severity of solicited local (i.e., injective site) and systemic (such as fever) AEs during the first 7 days following each dose of vaccine.
Interventions
- OTHER Placebo
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 1 |
What the finished NCT05525546 record still lists
NCT05525546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05525546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05525546 about?
NCT05525546 is a clinical study titled "Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease". This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
What is the current status of trial NCT05525546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2022-08-15. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT05525546?
The interventions under investigation include: Placebo (OTHER), Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation (BIOLOGICAL), Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation (BIOLOGICAL), Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05525546?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05525546's enrollment target sits among peer trials
82 669th of 2000 higher than 1,330 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI